Drugs / SKB575
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07488065 | Mar 2026 → Dec 2027 expected | atopic eczema | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2026-07-15 | Harbour BioMed (Guangzhou) Co. Ltd. | Regulatory Harbour BioMed and Kelun-Biotech Announce NMPA Approval of IND Application for HBM7575/SKB575 for the Treatment of Asthma harbourbiomed.com ↗ |
| 2026-07-15 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Regulatory Kelun-Biotech and Harbour BioMed Announce NMPA Approval of IND Application for SKB575/HBM7575 for the Treatment of Asthma kelun-biotech.com ↗ |
| 2026-03-10 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Regulatory Kelun-Biotech and Harbour BioMed Announce NMPA Approval of IND Application for SKB575/HBM7575 for the Treatment of Atopic Dermatitis kelun-biotech.com ↗
We are delighted to see the approval of SKB575/HBM7575 for clinical trials in atopic dermatitis. |
| 2026-03-09 | Harbour BioMed (Guangzhou) Co. Ltd. | Regulatory Harbour BioMed and Kelun-Biotech Announce NMPA Approval of IND Application for HBM7575/SKB575 for the Treatment of Atopic Dermatitis harbourbiomed.com ↗ |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-07-15 | Harbour BioMed (Guangzhou) Co. Ltd. | Harbour BioMed and Kelun-Biotech Announce NMPA Approval of IND Application for HBM7575/SKB575 for the Treatment of Asthma harbourbiomed.com ↗ |
| 2026-07-15 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Kelun-Biotech and Harbour BioMed Announce NMPA Approval of IND Application for SKB575/HBM7575 for the Treatment of Asthma kelun-biotech.com ↗ |
| 2026-03-10 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Kelun-Biotech and Harbour BioMed Announce NMPA Approval of IND Application for SKB575/HBM7575 for the Treatment of Atopic Dermatitis kelun-biotech.com ↗ |
| 2026-03-09 | Harbour BioMed (Guangzhou) Co. Ltd. | Harbour BioMed and Kelun-Biotech Announce NMPA Approval of IND Application for HBM7575/SKB575 for the Treatment of Atopic Dermatitis harbourbiomed.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SKB575 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07488065 ↗ |
| Known as | HBM7575 | “A Study of SKB575 (HBM7575) Injection in Healthy Participants and Atopic Dermatitis Participants” NCT07488065 ↗ |
| Route | Subcutaneous | “Route of administration: Subcutaneous injection” NCT07488065 ↗ |